Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499328 · ClinicalTrials.gov registry record · Phase 1
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 340
- Enrollment target
NCT02499328 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 340 participants.
The verdict
NCT02499328, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 340 participants
- Enrollment target
Study Summary
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Interventions
- DRUG MEDI4736
- DRUG AZD9150
- DRUG AZD5069
- DRUG tremelimumab (treme)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2015-08-06 |
| Est. Completion | 2025-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499328
The ClinicalTrials.gov registry entry for NCT02499328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MEDI4736 is the first listed.
NCT02499328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499328 about?
NCT02499328 is a clinical study titled "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck". This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
What is the current status of trial NCT02499328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 340 participants. The study started on 2015-08-06. Estimated completion is 2025-10-08.
What interventions are being tested in trial NCT02499328?
The interventions under investigation include: MEDI4736 (DRUG), AZD9150 (DRUG), AZD5069 (DRUG), tremelimumab (treme) (DRUG).
Who is sponsoring clinical trial NCT02499328?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.